Strongly activates TGR5. Weak GLP1 receptor agonism. Strongly inhibits DYRK1A. Hypoglycemic overall effect on prolonged usage.
Formulated for pancreatic repair and enhanced insulin sensitivity.
Upgregulation of UCP-1 in the white adipose tissue resulting in weight loss. Depletes stored fat. Promotes satiety, improves caloric utilisation and gut health. Mitigates hypercholestrolemia. Improves cardiovascular health.
Exigencin mediates blood fibrinolysis. Delays and prevents blood clotting. May acts as blood thinner.
